Abbott announced that LVAD therapy has been elevated from a Class IIa to a Class I recommendation in the updated 2026 ESC Heart Failure Guidelines for select patients with advanced HFrEF.
Public source
Publisher name
Public post
LVAD therapy has been elevated from a Class IIa to a Class I recommendation in the updated 2026 ESC Heart Failure Guidelines. For select patients with advanced HFrEF des…
Company
Abbott
- Industry
- Hospitals and Health Care
- Location
- Abbott Park, US
- Company size
- 10,001+ employees
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.html Privacy Policy: https://abbo.tt/privacy
See moreDiscover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Johnson & Johnson MedTech
Johnson & Johnson MedTech noted that Impella is now recognized as Class 2a by the ESC for select patients in the AMI-CS trial
Legal & Regulatory
American College of Cardiology
American College of Cardiology expanded its Chest Pain Center Accreditation with a CV Shock Designation focused on helping hospitals identify cardiogenic shock earlier, activate care teams faster, implement structured escalation pathways, and track outcomes.
Legal & Regulatory
MicroPort CardioFlow
MicroPort CardioFlow announced that the VitaFlow SELFValve™ transcatheter mitral valve replacement system has been officially accepted into the National Medical Products Administration’s (NMPA) Innovation Green Channel special review pathway for innovative medical devices.
Legal & Regulatory
InnovHeart